## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

#### FORM 8-K

#### **CURRENT REPORT**

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 26, 2017

### **GENTHERM INCORPORATED**

(Exact name of registrant as specified in its charter)

Michigan (State or other jurisdiction of incorporation) 0-21810 (Commission File Number) 95-4318554 (I.R.S. Employer Identification No.)

21680 Haggerty Road, Northville, MI (Address of principal executive offices)

48167 (Zip Code)

Registrant's telephone number, including area code: (248) 504-0500

Former name or former address, if changed since last report: N/A

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the ollowing provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this hapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company $\square$
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any ew or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. $\Box$

#### Item 2.02 Results of Operations and Financial Condition.

On October 26, 2017, Gentherm Incorporated (the "Company") publicly announced its financial results for the third quarter of 2017. A copy of the Company's news release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The information in this Item 2.02 and the attached exhibit shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act except as shall be expressly stated by specific reference in such filing.

#### Item 9.01 Financial Statements and Exhibits.

#### (d) Exhibits

Exhibit 99.1 Company news release dated October 26, 2017 concerning financial results.

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

#### GENTHERM INCORPORATED

By: /s/ Kenneth J. Phillips

Kenneth J. Phillips

Vice-President and General Counsel

Date: October 26, 2017



#### **Gentherm Reports 2017 Third Quarter Results**

Soft Quarter in Revenue and Margins but Fourth Quarter Appears Stronger

NORTHVILLE, Mich., October 26, 2017 /PRNewswire/ -- Gentherm (NASDAQ-GS:THRM), the global market leader and developer of innovative thermal management technologies, today announced its financial results for the third quarter ended September 30, 2017.

#### Key takeaways from third quarter operating results

- Consolidated third quarter revenue growth, slightly over 1%, was the slowest rate for the year due to automotive production cuts, a continued shift in CCS programs to the lower priced Heated and Ventilated version on some programs and a \$2.0 million special rebate to a customer. Automotive production in North America, our most important market, was lower by nearly 10% during the third quarter 2017 as compared with the same period in 2016.
- Revenue growth of 2% in the industrial segment did less to offset the slow automotive segment growth rate, unlike the first and second quarters of 2017 when the industrial segment grew by over 30%. Lower GPT revenue related to the timing of large program shipments is expected to be offset by higher fourth quarter revenue.
- Fourth quarter revenue forecast of \$245 to \$250 million is expected to bring the 2017 full-year growth rate to 6.1% 6.6% over the prior year.
- Gross margin and gross margin percentage was lower due to operational and non-recurring impacts, including the special rebate, unfavorable product mix and continued cost overruns in the CSZ custom environmental test chamber business.
- Higher selling, general and administrative expenses include \$2.5 million in CEO transition costs.
- Continued Euro strength resulted in significant unrealized foreign currency loss of \$6.0 million, mainly due to US Dollar cash held in Europe.
- Effective tax rate was lower due to favorable impact of the research and development tax credit.
- 163,000 common shares were repurchased during the quarter.

"The third quarter revenue was a disappointment. Production shut-downs at our automotive customers, a slower revenue ramp-up from our medical direct sales force initiative and the deferral of a large GPT product shipment to the fourth quarter all weighed heavily on our short-term revenue growth; however, an improved automotive production outlook and a tail wind from the GPT revenue deferral should lead to a stronger fourth quarter." said President and CEO Daniel R. Coker. "Lower gross and operating margins included several special expenses, some of which are not expected to recur." Coker added.

Coker continued, "We are proceeding with a robust level of investment in new and improved products, advanced technologies and updates in our business applications. During the third quarter, however, higher net research and development spending was offset with higher customer and government sponsored reimbursements. We are set to launch our advanced thermoelectric based Battery Thermal Management ("BTM") solution during the fourth quarter representing the first of these exciting new products. The advanced BTM revenue will significantly accelerate an already growing product category."

#### **Third Quarter 2017 Financial Review**

Product revenues for the third quarter 2017 increased by \$3.2 million, or 1.4% to \$235.9 million. This included an increase in the automotive segment totaling \$2.8 million, or 1.3%, to \$215.2 million, and an increase in the industrial segment of \$422,000, or 2.0%, to \$20.7 million. The increase in the automotive segment occurred despite lower automotive production volumes and a special rebate of \$2.0 million. Similar to the second quarter of 2017, our automotive OEM customers cut production on several vehicle programs through one-time plant shut-downs intended to adjust vehicle inventories. These shut-downs impacted our CCS programs disproportionately. CCS revenues were also reduced as a result of certain vehicle programs changing technologies from the higher priced active cooling seat application to heated and ventilated seat technology. Most of our other automotive products had higher revenue despite the weak production volumes. Steering wheel heaters were particularly strong, growing \$3.6 million, or 28%, to \$16.4 million. Seat heaters increased by \$3.3 million, or 4.4% to \$77.8 million. Product revenues from GPT, included in the industrial segment, totaled \$4.5 million which represented a decrease of \$620,000, or 12%. This decrease, which was even higher when compared to the GPT revenue totaling \$7.5 million during the 2017 second quarter, was mainly due to the deferral of a large customer project totaling \$4.0 million that has already shipped during the fourth quarter. Revenue for CSZ totaling \$16.2 million, which increased \$1.0 million, or 6.9%, offset the lower GPT revenue but was lower than the \$20.1 million in revenue during the second quarter of 2017. This sequentially lower revenue totaling \$3.9 million, or 19%, was partly due to \$2.8 million in lower environmental chamber revenue and partly due to lower medical product sales of \$1.1 million. The chamber sales were impacted by lower shipments of large custom chambers while the lower medical product revenues were due to lower sales of the blood heater cooler product that was higher during recent quarters due to regulatory issues affecting a competitor's product.

The special automotive customer rebate is a one-time lump-sum discount that reflects improved productivity gains that we expect to achieve through higher volume from new program awards.

The gross margin percentage decreased to 29.8%, during the third quarter, compared to 33.0% during the prior year third quarter mainly as a result of adjustments to our inventory reserves, the impact of the special rebate, higher production expenses and product mix changes. The unfavorable inventory adjustments totaled \$2.3 million and were mainly comprised of a reserve recorded for inventory held for the heated and cooled mattress product line and is based on a reduced sales outlook. Increased expenses totaling \$1.0 million included overtime and other costs incurred at our Mexico factories, labor expense inflation at our Ukraine factory, and factory launch expenses for the new advanced BTM program in our Macedonia facility. Other increased expenses include approximately \$830,000 in cost overruns in CSZ's industrial chamber business. Finally, we had an approximately \$2.8 million unfavorable impact from a shift in product mix due to the lower sales of the high margin revenue of GPT and CSZ's medical products as compared to 2016.

Selling, general and administrative expenses increased by \$4.8 million, or 16%, to \$34.3 million during the third quarter of 2017. This increase was partially due to expenses associated with the transition to a new chief executive officer, higher selling costs for CSZ's medical products business and increased management incentive compensation costs. On June 28, 2017 we announced the pending retirement of Daniel R. Coker, our CEO, and a related retirement compensation package. During the 2017 third quarter we recorded expenses totaling \$2.5 million, which included accelerated stock compensation amortization and a portion of a cash bonus owed to Mr. Coker upon his retirement. The amount also includes a signing bonus for Mr. Coker's successor and fees associated with the recruitment process. A similar CEO transition expense is expected to be recorded during the 2017 fourth quarter. CSZ's selling expenses increased by \$1.0 million mainly due to a program of hiring direct sales people for its medical division which began at the end of 2016. Other increases in selling, general and administrative expenses include business software implementation expenses associated with a new human resource management system and a new product lifecycle management application.

Income tax expense for the third quarter included a \$1.0 million benefit related to our research and development tax credit. Without the tax credit adjustment the effective tax rate, which was 9%, would have been 23%.

During the 2017 third quarter, we incurred a net foreign currency loss of \$7.3 million which included a net realized loss of \$1.3 million and a net unrealized loss of \$6.0 million. The unrealized loss was primarily the result of holding significant amounts of U.S. Dollar ("USD") cash at our subsidiaries in Europe and due to certain intercompany relationships between these European subsidiaries and our U.S. based companies.

The table below summarizes many of the significant amounts impacting the operating results for the third quarter 2017 as described above:

					<b>Earnings Before</b>		
			Impact on Gross	5	Income <u>Taxes</u>		
	Product	Gross	<u>Margin %</u>	Operating			Diluted
	Revenue	<u>Margir</u>		<b>Expenses</b>		<b>EBITDA</b>	<b>EPS</b>
			(In Mill	lions, except per	share data)(1)		
Non-routine expenses							
Customer rebate	\$(2.0)	\$(2.0)	-0.6%		\$(2.0)	\$(2.0)	\$(0.04)
Impairment of heat/cool mattress and other							
inventory reserve adjustments		(2.3)	-1.0%		(2.3)	(2.3)	(0.05)
CEO Transition expenses				(2.5)	(2.5)	(2.5)	(0.05)
Research and development tax credit							0.03
adjustment							
Operational issues							
Unrealized foreign currency loss on cash and							
intercompany balances					(6.0)	_	(0.13)
Product mix impact on shift of GPT revenue to	)						
fourth quarter		(1.0)	-0.4%		(1.0)	(1.0)	(0.02)
CSZ cost over-runs and unfavorable product		(1.8)	-0.7%		(1.8)	(1.8)	(0.04)
mix							

<sup>(1)</sup> Unfavorable amounts in brackets.

Our fully diluted earnings per share were \$0.18 and \$0.55 for the third quarter 2017 and 2016, respectively. As outlined in the accompanying table below entitled, "Acquisition Transaction Expenses, Purchase Accounting Impacts and Other Effects", these amounts included certain purchase accounting impacts from acquisitions and the unrealized currency loss. After adjusting for these impacts and effects, our fully diluted earnings per share would have been \$0.36 and \$0.61 in 2017 and 2016, respectively.

Total cash as of September 30, 2017 was \$147.6 million as compared with total cash of \$164.2 million at June 30, 2017. This decrease was primarily related to \$17.5 million in debt repayments and \$5.3 million used to repurchase common stock. The cash combined with \$220.7 million in borrowing availability under the Company's credit agreements, provides available liquidity totaling \$368.3 million as of September 30, 2017.

#### Guidance

Stronger fourth quarter revenue is expected to bring the full year growth rate for 2017 to approximately 6-7% over 2016 product revenue. Our guidance includes the extra quarter of CSZ revenue and assumes a neutral impact from foreign currency translation.

#### **Conference Call**

As previously announced, Gentherm is conducting a conference call today to be webcast at 8:00 AM Eastern Time to review these financial results. The dial-in number for the call is 1-877-407-4018 or, for international callers, 1-201-689-8471. The live webcast and archived replay of the call can be accessed on the Events page of the Investor section of Gentherm's website at <a href="https://www.gentherm.com">www.gentherm.com</a>.

A telephonic replay will be available at approximately 11:00 a.m. ET and will be accessible for two weeks. The replay can be accessed by dialing 1-844-512-2921, or for international callers, 1-412-317-6671. The passcode for the live call and the replay is 13672687.

Investor Relations Contact investors@gentherm.com 248-308-1702

#### **About Gentherm**

Gentherm (NASDAQ-GS: THRM) is a global developer and marketer of innovative thermal management technologies for a broad range of heating and cooling and temperature control applications. Automotive products include variable temperature Climate Control Seats, TrueTherm® cupholder and storage bins, heated automotive interior systems (including heated seats, steering wheels, armrests and other components), battery thermal management systems, cable systems and other electronic devices. Non-automotive products include remote power generation systems, heated and cooled furniture, patient temperature management systems, industrial environmental test chambers and related product testing services and other consumer and industrial temperature control applications. The Company is also developing a number of new technologies and products that will help enable improvements to existing products and to create new product applications for existing and new markets. Gentherm has over thirteen thousand employees in facilities in the United States, Germany, Canada, China, Hungary, Japan, Korea, Macedonia, Malta, Mexico, United Kingdom, Ukraine, and Vietnam. For more information, go to www.gentherm.com.

Except for historical information contained herein, statements in this release are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements represent Gentherm Incorporated's goals, beliefs, plans and expectations about its prospects for the future and other future events. The forward-looking statements included in this press release are made as of the date hereof or as of the date specified and are based on management's current expectations and beliefs. Such statements are subject to a number of important assumptions, risks, uncertainties and other factors that may cause the Company's actual performance to differ materially from that described in or indicated by the forward looking statements. Those risks include, but are not limited to, risks that new products may not be feasible, sales may not increase, additional financing requirements may not be available, new competitors may arise, currency exchange rates may change, and adverse conditions in the industry in which the Company operates may negatively affect its results. The foregoing risks should be read in conjunction with other cautionary statements included herein, as well as in the Company's annual report on Form 10-K for the year ended December 31, 2016 and subsequent reports filed with the Securities and Exchange Commission. Except as required by law, the Company expressly disclaims any obligation or undertaking to update any forward-looking statements to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

TABLES FOLLOW

# CONSOLIDATED CONDENSED STATEMENTS OF INCOME (In thousands, except per share data) (Unaudited)

	Three Months Ended September 30,					Nine Months Ended September 30,				
		2017		2016		2017		2016		
Product revenues	\$	235,853	\$	232,625	\$	728,498	\$	681,059		
Cost of sales		165,624		155,931		494,704		464,628		
Gross margin		70,229		76,694		233,794		216,431		
Operating expenses:										
Net research and development expenses		19,721		19,745		60,633		54,552		
Acquisition transaction expenses		_		22		_		693		
Selling, general and administrative expenses		34,331		29,512		96,912		81,533		
Total operating expenses		54,052		49,279		157,545		136,778		
Operating income		16,177		27,415		76,249		79,653		
Interest expense		(1,250)		(660)		(3,633)		(2,287))		
Foreign currency (loss) gain		(7,340)		(873)		(21,920)		88		
Other income (expense)		(403)		359		6		754		
Earnings before income tax		7,184		26,241		50,702		78,208		
Income tax expense		630		6,018		10,233		27,646		
Net income	\$	6,554	\$	20,223	\$	40,469	\$	50,562		
Basic earnings per share	\$	0.18	\$	0.55	\$	1.10	\$	1.39		
Diluted earnings per share	\$	0.18	\$	0.55	\$	1.10	\$	1.38		
Weighted average number of shares – basic		36,742		36,477		36,713		36,426		
Weighted average number of shares – diluted		36,805		36,595		36,831		36,558		

### REVENUE BY PRODUCT CATEGORY (Unaudited, in thousands)

Three Months Ended

**Nine Months Ended** 

September 30, September 30, 0/6 % 2016(1) Diff. 2017 2016(1) Diff. 2017 Climate Controlled Seat (CCS) 93,703 99,770 -6.1% 294,564 \$ 303,562 -3.0% Seat Heaters 77,793 74,506 4.4% 229,242 217,372 5.5% Steering Wheel Heaters 16,439 12,889 27.5% 45,983 37,001 24.3% 11.2% 67,329 Automotive Cables 23,645 21,265 64,031 5.2% Battery Thermal Management (BTM) (2) 2,754 1,504 83.1% 7,181 4,785 50.1% Other Automotive (3) 841 2,435 -65.5% 8,521 7,885 8.0% 215,175 Subtotal Automotive 212,369 1.3% 652,820 634,636 2.9% Remote Power Generation (GPT) 4,492 5,112 -12.1% 19,405 14,494 33.9% 6.9% Cincinnati Sub-Zero Products (CSZ) 16,186 15,144 56,273 31,929 76.2% 232,625 235,853 1.4% 728,498 681,059 **Total Company** 7.0%

<sup>(1)</sup> During First Quarter 2017 we revised our revenue by product analysis to better reflect pricing adjustments and other differences. We have revised prior year revenue by product amounts to reflect this change.

<sup>(2)</sup>Battery Thermal Management or BTM product revenues currently includes Gentherm's automotive grade, low cost, heat resistant fans and blowers used by customers for battery cooling through ventilation. The advanced TED based active cool system is scheduled to begin serial production during the 2017 fourth quarter.

<sup>(3)</sup> Includes \$2.0 million rebate to customer during 2017.

## RECONCILIATION OF NET INCOME TO ADJUSTED EBITDA (Unaudited, in thousands)

	Three Mo	Nine Months Ended								
	September 30,					September 30,				
	2017		2016		2017		2016			
Net Income	\$ 6,554	\$	20,223	\$	40,469	\$	50,562			
Add Back:										
Income tax expense	630		6,018		10,233		27,646			
Interest expense	1,250		660		3,633		2,287)			
Depreciation and amortization	11,399		10,129		32,447		27,599			
Adjustments:										
Acquisition transaction expense			22				693			
Unrealized currency loss (gain)	6,039		24		19,425		189			
Adjusted EBITDA	\$ 25,872	\$	37,076	\$	106,207	\$	108,976			

#### **Use of Non-GAAP Financial Measures**

In evaluating its business, Gentherm considers and uses Adjusted EBITDA as a supplemental measure of its operating performance. The Company defines Adjusted EBITDA as earnings before interest, taxes, depreciation and amortization, deferred financing cost amortization, transaction expenses, debt retirement expenses, unrealized currency gain or loss and unrealized revaluation of derivatives. Management believes that Adjusted EBITDA is a meaningful measure of liquidity and the Company's ability to service debt because it provides a measure of cash available for such purposes. Management provides an Adjusted EBITDA measure so that investors will have the same financial information that management uses with the belief that it will assist investors in properly assessing the Company's performance on a period-over-period basis.

The term Adjusted EBITDA is not defined under GAAP, and is not a measure of operating income, operating performance or liquidity presented in accordance with GAAP. Adjusted EBITDA has limitations as an analytical tool, and when assessing the Company's operating performance, investors should not consider Adjusted EBITDA in isolation, or as a substitute for net income or other consolidated income statement data prepared in accordance with GAAP. Gentherm compensates for these limitations by relying primarily on its GAAP results and using Adjusted EBITDA only supplementally.

## ACQUISITION TRANSACTION EXPENSES, PURCHASE ACCOUNTING IMPACTS AND OTHER EFFECTS

(Unaudited and in thousands, except per share data)

	7	Three Months Ended Nine Months Ended			Ended													
		Septem	ber :	30,	September 30,				Future Full Year Periods (estimated)									
		2017		2016		2017		2016		2017		2018		2019		2020	Th	ereafter
Transaction related current expenses																		
Acquisition transaction expenses	\$	_	\$	22	\$	_	\$	693	\$	_	\$	_	\$	_	\$	_	\$	_
Non-cash purchase accounting impacts																		
Customer relationships amortization		2,057		1,964		5,883		5,696		8,272		8,272		6,094		4,788		16,851
Technology amortization		937		891		2,151		2,541		2,827		1,335		769		769		1,538
Product development costs amortization		_		42		_		42		_		_		_		_		_
Trade name amortization		46		44		131		130		138		_		_		_		_
Inventory fair value adjustment		_		_		_		3,973		_		_		_		_		_
Other effects																		
Unrealized currency loss		6,039		24		19,422		189		_		_		_		_		_
Total acquisition transaction expenses,																		
purchase accounting impacts and																		
other effects	\$	9,079	\$	2,987	\$	27,587	\$	13,264	\$	11,237	\$	9,607	\$	6,863	\$	5,557	\$	18,389
Tax effect of above		(2,374)		(743)		(7,250)		(3,821)		(2,795)		(2,415)		(1,779)		(1,477)		(5,504)
North America reorganization																		
withholding tax (1)							_	9,600	_									
Net income effect	\$	6,705	\$	2,244	\$	20,337	\$	19,043	\$	8,442	\$	7,192	\$	5,084	\$	4,080	\$	12,885
					_	_	_	,						,		,		_
Earnings per share - difference																		
Basic	\$	0.18	\$	0.06	\$	1.10	\$	0.52										
Diluted	\$	0.18	\$	0.06	\$	1.10	\$	0.52										

<sup>(1)</sup> During the first quarter of 2016, we completed a legal reorganization in North America by shifting certain operations located in Canada to other subsidiaries. Related to the reorganization we declared intercompany dividends and incurred \$9.6 million in withholding taxes payable to the Canadian Revenue Agency.

#### CONSOLIDATED BALANCE SHEETS

(In thousands, except share data) (Unaudited)

	Sej	ptember 30, 2017	December 31, 2016		
ASSETS					
Current Assets:					
Cash and cash equivalents	\$	147,626	\$	177,187	
Accounts receivable, less allowance of \$1,082 and \$1,391, respectively		182,236		170,084	
Inventory:					
Raw materials		59,399		60,525	
Work in process		19,382		13,261	
Finished goods		34,604		31,288	
Inventory, net		113,385		105,074	
Derivative financial instruments		1,542		18	
Prepaid expenses and other assets		37,034		32,000	
Total current assets		481,823		484,363	
Property and equipment, net		190,825		172,052	
Goodwill		54,287		51,735	
Other intangible assets, net		52,520		57,557	
Deferred financing costs		1,008		1,221	
Deferred income tax assets		44,564		35,299	
Other non-current assets		37,561		40,803	
Total assets	\$	862,588	\$	843,030	
LIABILITIES AND SHAREHOLDERS' EQUITY		_			
Current Liabilities:					
Accounts payable	\$	80,322	\$	84,511	
Accrued liabilities		65,519		105,625	
Current maturities of long-term debt		3,445		2,092	
Derivative financial instruments				1,395	
Total current liabilities		149,286		193,623	
Pension benefit obligation		8,170		7,419	
Other liabilities		5,207		4,092	
Long-term debt, less current maturities		142,446		169,433	
Deferred income tax liabilities		6,674		8,058	
Total liabilities		311,783		382,625	
Shareholders' equity:					
Common Stock:					
No par value; 55,000,000 shares authorized, 36,677,528 and 36,534,464 issued and outstanding at					
September 30, 2017 and December 31, 2016, respectively		262,935		262,251	
Paid-in capital		14,206		10,323	
Accumulated other comprehensive loss		(25,223)		(69,091)	
Accumulated earnings		298,887		256,922	
Total shareholders' equity		550,805	_	460,405	
Total liabilities and shareholders' equity	\$	862,588	\$	843,030	

#### CONSOLIDATED STATEMENTS OF CASH FLOWS

#### (In thousands)

(Unaudited)

	Nin	tember 30,					
		2017	2016				
Operating Activities:							
Net income	\$	40,469	\$	50,562			
Adjustments to reconcile net income to cash provided by operating activities:							
Depreciation and amortization		32,663		27,724			
Deferred income taxes		(9,059)		(1,933)			
Stock compensation		8,559		6,856			
Defined benefit plan expense		96		151			
Provision of doubtful accounts		(353)		385			
Loss on sale of property and equipment		868		291			
Changes in operating assets and liabilities:							
Accounts receivable		(5,581)		(22,835)			
Inventory		(4,407)		(5,647)			
Prepaid expenses and other assets		(555)		2,826			
Accounts payable		(7,433)		6,508			
Accrued liabilities		(39,896)		6,123			
Net cash provided by operating activities		15,371		71,011			
Investing Activities:							
Proceeds from the sale of property and equipment		41		45			
Acquisition of subsidiary, net of cash acquired		(2,000)		(73,593)			
Purchases of property and equipment		(37,181)		(50,742)			
Net cash used in investing activities		(39,140)		(124,290)			
Financing Activities:							
Borrowing of debt		_		75,000			
Repayments of debt		(25,906)		(32,368)			
Excess tax expense from equity awards				(277)			
Cash paid for financing costs		_		(650)			
Cash paid for the cancellation of restricted stock		(1,100)		(1,196)			
Cash paid for the repurchase of Common Stock		(5,326)					
Proceeds from the exercise of Common Stock options		2,434		1,038			
Net cash (used in) provided by financing activities		(29,898)		41,547			
Foreign currency effect		24,106		66			
Net decrease in cash and cash equivalents		(29,561)		(11,666)			
Cash and cash equivalents at beginning of period		177,187		144,479			
Cash and cash equivalents at end of period	\$	147,626	\$	132,813			
Supplemental disclosure of cash flow information:	<del>-</del>	.,	-	3-,3			
Cash paid for taxes	\$	67,160	\$	18,183			
	\$	3,171	\$	1,963			
Cash paid for interest	<u>Ф</u>	3,1/1	Þ	1,903			
Supplemental disclosure of non-cash transactions:	<b>.</b>	o o==	Φ.	0 =0=			
Common Stock issued to Board of Directors and employees	\$	3,873	\$	3,507			